Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Publication of Tokmanni's Half year financial report

Tokmanni Group Corporation                      Press release 27.7.2017       10.00 am EEST                     Tokmanni Group Corporation will publish its Half year financial report for January-June 2017 on August 9, 2017 Tokmanni will publish its Half year financial report for January-June 2017 on August 9 at approximately 8.30 a.m. EEST (7.30 CET). The stock exchange release and the presentation materials in Finnish and in English will be available on the company's website at ir.tokmanni.fi as soon as possible after the publication of the report. Analyst and press briefing An

Major labour shortages in the business sector

The Economic Tendency Indicator edged up from 112.2 in June to 112.4 in July and continues to signal very positive sentiment in the economy.  All of the business indicators show a stronger or much stronger situation than normal, the most optimistic sector being manufacturing. The consumer confidence indicator fell slightly but remains above the historical average.The manufacturing industry continues to report a much stronger situation than normal, with the confidence indicator rising slightly to 120.3 in July from 119.9 in June. Firms’ overall assessment of their order books is the most

Tagrisso significantly improves FLAURA

This announcement contains inside information 27 July 2017 07:15 BST TAGRISSO SIGNIFICANTLY IMPROVES PROGRESSION-FREE SURVIVAL IN THE PHASE III FLAURA TRIAL FOR LUNG CANCER Tagrisso met the primary endpoint, demonstrating a statistically-significant and clinically-meaningful progression-free survival benefit in 1st-line EGFRm non-small cell lung cancer compared to current standard-of-care treatment AstraZeneca today announced that the Phase III FLAURA trial showed a statistically-significant and clinically-meaningful progression-free survival (PFS) benefit with Tagrisso (

AZ reports initial results from MYSTIC lung trial

This announcement contains inside information   27 July 2017 07:10 BST ASTRAZENECA REPORTS INITIAL RESULTSFROM THE ONGOING MYSTIC TRIAL IN STAGE IV LUNG CANCER Imfinzi plus tremelimumab combination did not meet a primary endpoint of progression-free survival compared to chemotherapy The MYSTIC trial continues as planned to assess the additional primary endpoints of overall survival for Imfinzi monotherapy and for the Imfinzi plus tremelimumab combination AstraZeneca and MedImmune, its global biologics research and development arm, today announced progression-free

AZ & MERCK ESTABLISH STRATEGIC ONCOLOGY DEAL

This announcement contains inside information   27 July 2017 07:05 BST ASTRAZENECA AND MERCK ESTABLISH STRATEGIC ONCOLOGY COLLABORATION Collaboration aims to maximise the potential of PARP and MEK inhibitors in combination with PD-L1/PD-1 medicines, based on growing scientific evidence that these combinations offer new potential for the treatment of a range of tumour types AstraZeneca and Merck will independently develop and commercialise Lynparza and potential medicine selumetinib in combinations with companies' respective PD-L1/PD-1 immuno-oncology medicines Imfinzi and

Additional preliminary interim results from intralymphatic study with Diamyd® published as part of scientific correspondence in NEJM

New immunological data from the DIAGNODE-1 trial, published as part of a correspondence in the medical periodical New England Journal of Medicine, show a predominant Th2 response when the diabetes vaccine Diamyd® is administered directly into the lymph node being stronger than observed when injecting it under the skin. The correspondence and data are based on the original article published in NEJM on February 16, 2017, by Professor Johnny Ludvigsson, Principal Investigator and sponsor of the open label pilot trial DIAGNODE-1. The authors of the correspondence letter comment that

Lehto Group Plc:Lehto Group Plc will publish the Half year financial report for January-June 2017 on August 10, 2017

Lehto Group Plc Press Release 27 July 2017, 9:00 a.m. EEST                        Lehto Group Plc will publish the Half year financial report for January-June 2017 on August 10, 2017 Lehto Group will publish the Half year financial report for January-June 2017 on Thursday, August 10, 2017, at 8:30 a.m. Finnish time (EEST). The Half year financial report and presentation material related to the report will be available in both Finnish and English at the company's website www.lehto.fi/en/investors. Press conference for investors and media Lehto Group will hold a press

Attendo's report for the second quarter 2017: Attendo continues to invest to meet growing demand

Attendo continues to invest in new nursing homes and acquisitions to meet a growing demand for care services. Attendo’s profit for the second quarter 2017 increased somewhat compared with the corresponding quarter of 2016, despite negative calendar effects.Comments by Henrik Borelius, CEO: “Attendo continued to invest for future growth in the second quarter of 2017, partly by increasing the number of beds under construction and partly through a number of acquisitions. The acquisition of Mikeva strengthens Attendo’s Finnish operations in care for older people while establishing a leading

Loomis Interim report April – June 2017

April – June 2017Revenue for the second quarter increased to SEK 4,346 million (4,147). Organic growth was 2 percent (6) and real growth was 2 percent (8). Loomis operating income (EBITA)1) amounted to SEK 517 million (444) and the operating margin was 11.9 percent (10.7). Income before taxes amounted to SEK 463 million (398) and income after taxes was SEK 332 million (286). Earnings per share before and after dilution amounted to SEK 4.41 (3.81). Cash flow from operating activities amounted to SEK 437 million (513), equivalent to 85 percent (116) of operating income (EBITA).

Outotec's Half year financial report 2017

OUTOTEC OYJ HALF YEAR FINANCIAL REPORT JULY 27, 2017 AT 9:00 AM   HALF YEAR FINANCIAL REPORT 2017   Good development in Minerals Processing, recovery of Metals, Energy & Water pending "Our half year order intake improved significantly from last year, reflecting a more positive market sentiment in the mining industry. Our Minerals Processing segment, whose market activity started to improve in the second quarter last year, continued to develop well and its profitability improved. During the reporting period, our order intake increased by 34% from last year. Service order intake

Systemair's Annual General Meeting on 24 August 2017

Press Release, 27 July 2017 Systemair AB (publ) (NASDAQ OMX Stockholm: SYSR) with broken fiscal year 1 May to 30 April, the Annual General Meeting will be held on Thursday, 24 August 2017 at 3 p.m. in the auditorium, Systemair Expo, in Skinnskatteberg. Convening notice to the Annual General Meeting, the proposed agenda and the proposed decisions in its entirety, is attached to this press release and published on the company's website www.systemair.com. On the website there is also a proxy form and the ability to sign up for participation in the Annual General Meeting. The notice of

NattoPharma Selects Industry Veteran Jeff Lind to Lead Sales Team

OSLO, NORWAY and METUCHEN, NJ (27 July 2017) – As the established Vitamin K2 R&D leader, NattoPharma has invited a supplement industry veteran with an equally respected reputation to join its team. In line with the company’s efforts to increase its global commercial activites, NattoPharma is pleased to announce it has named Jeff Lind as its Vice President of Sales, Americas. Working in some of the most respected companies in the natural products industry for more than 20 years in various leadership roles, Lind comes to NattoPharma from Natreon, Inc., where he served as the Vice President

Interim report January - June 2017

April – June 2017 · Consolidated revenue for the period was SEK 275.9 M (104.5), an increase of 164 per cent compared to 2016.  · EBIT for the period was SEK 32.1 M (8.7), an increase of 268 per cent compared to 2016.  · Net result for the period was SEK 29.0 M (7.8). · Earnings per share for the period, before dilution, was SEK 3.30 (0.89). · Cash flow before financing activities during the period was SEK 7.0 M (-4.5). Dividend impacted cash flow with -6.6 (0.0) MSEK and cash flow amounted to 0.4 (-4,5) MSEK. · For the free-to-play games the average Monthly Active Users

Notice to YIT Corporation’s Extraordinary General Meeting

YIT Corporation Stock Exchange Release July 27, 2017 at 08:10 a.m.The shareholders of YIT Corporation ("YIT" or the "Company") are invited to attend the Extraordinary General Meeting to be held on Tuesday, September 12, 2017, starting at 10.00 am (Finnish time GMT+2) in Hall A of the Congress Wing at the Finlandia Hall, located at the address Mannerheimintie 13, Helsinki (entrance through doors M1 and K1). Check-in for those who have registered for the meeting, distribution of ballots and serving of coffee will start at the venue at 9.00 am. Registration for the meeting must be made no

YIT's Half-Year Report January 1 – June 30, 2017: Profitability continued to improve, Finland and the CEE countries as the driver

YIT Corporation Stock Exchange Release July 27, 2017 at 8:00 a.m.Unless otherwise noted, the figures in brackets refer to the corresponding period in the previous year and are of the same unit. Segment reporting, POC Residential projects for consumers recognised as income in line with degree of sales and construction1 April–June • Revenue remained stable and was EUR 457.8 million (463.7). • Adjusted operating profit amounted to EUR 25.0 million (20.2), and adjusted operating profit margin was 5.5% (4.3). • EUR -1.1 million of adjusting items were booked in the period

UTA physics Ph.D. graduate’s journey to success took him from Africa to UTA

Last Feremenga, a native of Zimbabwe who received his doctoral degree in December, used skills he honed at UTA while analyzing massive quantities of data from the Large Hadron Collider particle physics experiment in Switzerland to land a job as a data scientist. The educational journey taken by Last Feremenga has been exciting, fascinating and has involved plenty of air travel. It began in his native Zimbabwe, continued first in Chicago and then in Arlington, and included frequent trips between Arlington, Chicago and Europe. Feremenga, who received a doctorate in Physics and Applied

NOTICE OF EXTRAORDINARY GENERAL MEETING OF CYBAERO AB (PUBL)

Shareholders of CybAero AB (publ) are hereby summoned to an Extraordinary General Meeting on Thursday, August 24th2017 at 10.00 CEST at the company facilities at Teknikringen 7, Mjärdevi Science Park, Linköping, Sweden. The EGM will be open for registration at 09.00, register before 09.45.  Notifications etc. Shareholders who wish to attend the meeting must: -        Be registered in the Euroclear Sweden AB (”Euroclear”) share register as of Friday, August 18th2017. -        Notify the company of their attendance no later than Monday, August 21stat 13.00 CEST. Notification of

Major League Baseball Players Alumni Association Brings Legends for Youth Baseball Clinic Series to Springfield, IL

Free youth baseball clinic to feature Brian Boehringer, Jim Mecir and other MLB AlumniColorado Springs, Colo. – Local youth will have an opportunity to play with their big league heroes at the Major League Baseball Players Alumni Association (MLBPAA) Legends for Youth baseball clinic series on Saturday, July 29th, 2017. In conjunction with the Hanover Insurance Group , the free clinic features former Major League Baseball players who will teach baseball skills, drills and life lessons for approximately 200 local youth.   Players attending* include 1996 New

Navamedic ASA: Presentation of second quarter figures

Navamedic ASA invites you to follow an online presentation of the second quarter 2017 figures. The presentation will be webcasted at www.navamedic.com - investor relations - presentations - webcast on Friday 28.07 2017 at 8 AM.  Shortly after the presentation the webcast recording will be published at the same site. This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.

#17-710 Listing of Turbo warrants issued by Commerzbank AG

As from July 27, 2017, 2 Turbo warrants issued by Commerzbank AG will be listed on NDX Sweden and will be included on the list for Knock-Outs. The instruments will be registered at Euroclear Sweden AB.Issuer: Commerzbank AG Type of security: Call Turbo warrants of European type Execution: Automatic cash settlement Term: As from July 27, 2017 to expiry date Market Maker: Commerzbank AG Underlying: DAX 30 Index For more details see attached file. For further information concerning this NDX notice please contact: NDX Listing on +46 8 566 390 20 or at ndxlist@ngm.se

#17-709 Listing of Knock out warrants issued by Commerzbank AG

As from July 27, 2017, 41 Knock out warrants issued by Commerzbank AG will be listed on NDX Sweden and will be included on the list for Knock-Outs. The instruments will be registered at Euroclear Sweden AB.Issuer: Commerzbank AG Type of security: Knock out warrants, open ended Execution: Automatic cash settlement Term: As from July 27, 2017 and forward or until time for knock out event Market Maker: Commerzbank AG Underlying: ABB Ltd Alfa Laval AB Assa Abloy AB ser.B AstraZeneca PLC Atlas Copco AB Ser. A Boliden AB Electrolux AB ser. B

#17-708 Listing of Knock out warrants issued by SG Issuer

As from July 27, 2017, 4 Knock out warrants issued by SG Issuer will be listed on NDX Sweden and will be included on the list for Knock-Outs. The instruments will be registered at Euroclear Sweden AB.Issuer: SG Issuer Type of security: Knock out warrants, open ended Execution: Automatic cash settlement Term: As from July 27, 2017 and forward or until time for knock out event Market Maker: Societe Generale Underlying: DAX 30 Index Current values of strike and barrier can be found at: [ NGM Market Data Web - KnockOutWarrants ] 

#17-707 Listing of Turbo warrants issued by BNP Paribas Issuance B.V.

As from July 27, 2017, 2 Turbo warrants issued by BNP Paribas Issuance B.V. will be listed on NDX Sweden and will be included on the list for Knock-Outs. The instruments will be registered at Euroclear Sweden AB.Issuer: BNP Paribas Issuance B.V. Type of security: Call and put Turbo warrants of European type Execution: Automatic cash settlement Term: As from July 27, 2017 to expiry date Market Maker: BNP Paribas Arbitrage SNC Underlying: DAX 30 Index For more details see attached file. For further information concerning this NDX notice please contact: NDX Listing

There are no items matching the current filter
There are no more items matching the current filter
Back to top